(2013–2019) were used to create four pair-wise comparison cohorts of type 2 diabetes patients with: (1a) HFrEF initiating SGLT2i versus DPP4i; (1b) HFrEF initiating SGLT2i versus GLP-1RA; (2a) HFpEF initiating SGLT2i versus DPP4i; and (2b) HFpEF initiating SGLT2i versus GLP-1RA....
Additionally, preclinical and preliminary clinical data suggest that DPP4-inhibitors hold interesting promise for cardiovascular protection. Since GLP-1 itself has favorable cardiovascular effects [3], [32] most of these protective effects of DPP4 inhibition are ascribed to the increased bioavailability of...
and is useful as a marker for various cancers,with its levels either on the cell surface or in the serum increased in some neoplasms and decreased in others. DPPIV also binds the enzyme adenosine deaminase specifically and with high affinity. The significance of this interaction has yet to be...
In diabetic patients, the increase of circulating DPP4 activity results in a reduction of plasma GLP-1 both at fasting and in response to the meal [49]. In addition to circulating DPP4 activity, expression of DPP4 on T cells was reported to increase in patients with T2DM [50]. However, ...
It is responsible for the degradation of incretins such as GLP-1. DPPIV plays an important role in tumor biology, and is useful as a marker for various cancers, with its levels either on the cell surface or in the serum increased in some neoplasms and decreased in others.DPPIV also ...
Additionally, LINC01132 knockdown significantly blocked the interaction between NRF1 and DPP4 (Fig. 5G). However, the effects were not observed for KDM5B. These results indicated that LINC01132 acts as a scaffold in the interaction between NRF1 and DPP4. LINC01132 improves the response to...
DPP4 is found throughout the body, but its activity is only partially understood. The enzyme does play significant roles ininflammatory responsesand insulin regulation. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. ...
Besides its action on insulin release, GLP-1 also regulates cholesterol and triglycerides. It reduces VLDL triglyceride production in the liver and regulates reverse cholesterol transport [43–48]. GLP-1 as well as GIP are rapidly inactivated by the enzyme, DPP4 [49], whose activity correlates ...
3.2.1. Physiological Role of DPP4 in Glycemic Control DPP4 is involved in the endogenous control of glycemia, being physiologically or pharmacology related to the degradation of glucagon, glucagon-like peptide-1 (GLP-1) and -2 (GLP-2), gastric inhibitory peptide or glucose-dependent insulinotropic...